Iovance Biotherapeutics

Patent cliffs & loss of exclusivity

Iovance Biotherapeutics is a late-stage oncology company with the potential to bring the first novel autologous T cell therapy to the market for solid tumors in patients with significant unmet needs.

Company

AngelList URLhttps://angel.co/company/iovance-biotherapeutics
Legal NameIovance Biotherapeutics, Inc.
Company Operating StatusActive
Crunchbase URLhttps://www.crunchbase.com/organization/lion-biotechnologies
Full Address825 Industrial Road, Suite 400 San Carlos, CA 94070
LinkedIn URLhttps://www.linkedin.com/company/iovance/about/
Pitchbook URLhttps://pitchbook.com/profiles/company/42262-12
Previous NameFREIGHT MANAGEMENT CORP

1 upcoming patent cliff

DrugIngredientTypeCliff
  1. AMTAGVILifileucelBiologicFeb 2036

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.

Iovance Biotherapeutics — patent cliffs & loss of exclusivity | CliffBio